Closed · RFA-DA-19-015 · CFDA 93.279 · Discretionary
Loyalty and Reward-Based Technologies to Increase Adherence to Substance Use Disorder Pharmacotherapies (R41/R42 - Clinical Trial Optional)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- December 14, 2018
- Close date
- -
- Expected awards
The verdict
Loyalty and Reward-Based Technologies to Increase Adherence to Substance Use Disorder Pharmacotherapies (R41/R42 - Clinical Trial Optional) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- Varies
- award range
- Closed
- application status
- 93.279
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
Loyalty and Reward-Based Technologies to Incr… is closed (last close December 14, 2018). The parent program page for CFDA 93.279 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed December 14, 2018
Instrument
Grant
Description
The purpose of this Funding Opportunity Announcement is to develop and evaluate the loyalty/reward-based digital technologies (e.g., mobile medical app/device platforms and other digital technologies) to be used as a combination product to increase medication adherence. The objective of Phase I (R41) is to establish the feasibility and/or validation of the device, and Phase 2 is designed to test the efficacy of the reward-based platform in a larger sample. The primary endpoint is adherence to FDA-approved medications for substance use disorders. Rewards and contingencies should be delivered in a self-sustaining manner and include a front-end interface allowing treatment providers to monitor progress and deliver rewards. Platforms may include novel features including, but not limited to, automated tracking tools, real-time assessments of patient progress, medication intake, and momentary assessment. Data generated from these studies are to be used to support a 510k submission to seek clearance as an FDA cleared device.
Small-business / for-profit corridor · RFA-DA-19-015
Loyalty and Reward-Based Technologies to Incr… prints a for-profit / small-business applicant door (Small businesses). Treat the listing as business-facing unless the full Grants.gov announcement narrows it further. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity codes span Education · Health (ED;HL). 789 other National Institutes of Health listings share this eligibility-code string (6% of 12,420).
- Code 23
- Small businesses
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Drug Abuse Research Programs
National Institutes of Health
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Loyalty and Reward-Based Technologies to Incr… is closed; use the parent program and agency catalog for the next funding cycle.
- Parent CFDA 93.279 may publish future NOFOs under the same assistance listing. Open program
- Drug Abuse Research Programs indexes 170 Grants.gov listings in this extract. Program profile
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |